Updates for 2023
FDLI remains committed to providing high-quality educational programs while keeping our members and event attendees safe during the current pandemic. With this in mind, we are excited to announce that the 2023 Annual Conference will be a hybrid event. Please know we are actively exploring options to ensure an engaging and enjoyable experience. Be sure to check the course website regularly for additional announcements and updates.
As the premier conference for the food and drug law community, the FDLI Annual Conference addresses complex legal, regulatory, compliance, and policy issues in all facets of the FDA-regulated industry. The conference provides in-depth discussions and analyses on a wide variety of timely topics by bringing together experts from the federal government, industry, the private bar, non-profit, patient and consumer advocates, consulting organizations, and academia.
Conference Highlights:
- Hear FDA’s strategic priorities directly from the FDA Commissioner, Chief Counsel, Center Directors, and other key leaders within the Agency
- Gain in-depth knowledge of each FDA Center by attending consecutive Center Director sessions scheduled to maximize attendee opportunities
- Join high-level colleagues in food and drug law to hear different viewpoints, shape policy, and advance understanding
- Select from over 30 breakout sessions covering the latest in legal, regulatory, compliance, policy, marketing, and related issues
- Learn from more than 100 well-known officials and experts
- Hear about the Top Cases in Food and Drug Law
- Network and build relationships with seasoned legal, regulatory, compliance, policy, and government professionals
Call For Proposals
FDLI and the Conference Planning Committee thanks those who participated in the Call for Proposals this fall. The input received from stakeholders helps us plan a timely and topical program. If you submitted a proposal, you will be notified of the status of your proposal in late January 2023.
Register by February 24!
Industry & Firms
- +$350 for non-members
- +$100 after 2/24/23
- +$200 after 3/31/23
Non-Profit
- +$200 for non-members
- +$100 after2/24/23
- +$200 after 3/31/23
Government
- +$200 for non-members
- +$100 after 2/24/23
- +$200 after 3/31/23
Academic
- +$200 for non-members
- +$100 after 2/24/23
- +$200 after 3/31/23
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
Sponsors
Sponsorship opportunities are available. Please let us know if you would like more information.
Planning Committee
Co-Chairs
MANTEJ (NIMI) CHHINA serves as Senior Director and Head of Global R&D and Regulatory Policy at BioMarin Pharmaceutical Inc. Nimi joined BioMarin in 2017 as Director, leading US Regulatory Policy. Prior to joining BioMarin, Nimi spent 7 years at the US Food and Drug Administration (FDA), where she served in multiple roles including as team lead in the Division of Medical Policy Development in the Center for Drug Evaluation and Research (CDER). Nimi received her MS (honors school) in human genetics from Guru Nanak Dev University in India; PhD in biotechnology and functional genomics from George Mason University, VA (USA); and JD from University of the District of Columbia David A. Clarke School of Law (USA). Also, she received the Regulatory Affairs Certification (RAC) as well as a certificate in legislative affairs from the Government Affairs Institute at Georgetown University, DC (USA). Nimi is based in the Washington, DC area, and is actively engaged on the R&D and regulatory policy development landscape.
JONATHAN A. HAVENS is a partner at Saul Ewing Arnstein & Lehr LLP, where he serves as co-chair of both the firm’s Cannabis Law and Food, Beverage & Agribusiness Practices. Companies in the cannabis (both hemp and marijuana), life sciences, food and beverage, and cosmetics industries turn to Jonathan for advice on how to get and keep their products on the market. Since 2019, Chambers USA has recognized Jonathan as one of America’s leading lawyers in cannabis law. In 2021, Law360 selected Jonathan as a cannabis law rising star, making him one of only five attorneys nationwide to receive that honor. He is regularly interviewed by mainstream and trade press outlets, alike, and has been quoted by or authored pieces for The New York Times, The Los Angeles Times, Reuters, CNBC, WIRED, MarketWatch, Engadget, Law360, High Times Magazine, and Marijuana Business Daily, among others. Jonathan began his legal career as a regulatory counsel with the US Food and Drug Administration, and prior to law school, Jonathan served as a legislative aide in both the US Senate and US House of Representatives.Committee
Stacy Cline Amin, Morrison and Foerster, LLP
Kenita Barrow, Otsuka America Pharmaceutical, Inc.
Jennifer L. Bragg, Skadden, Arps, Slate, Meagher & Flom LLP
Karen Day, Pfizer, Inc.
Colleen M. Heisey, Jones Day
August T. Horvath, Foley Hoag LLP
Elizabeth R. Jungman, CDER, FDA
Winston S. Kirton, BakerHostetler
Chad A. Landmon, Axinn, Veltrop & Harkrider LLP
Eric N. Lindblom, O’Neill Institute for National and Global Health Law, Georgetown Law
Sharon L. Mayl, DLA Piper LLP
Beth G. Oliva, Fox Rothschild LLP
Megan L. Olsen, Council for Responsible Nutrition
Ann M. Oxenham, CFSAN, FDA
Sarah H. Stec, Johnson & Johnson
Deborah E. Tolomeo, Spark Therapeutics
Anne K. Walsh, Hyman, Phelps & McNamara, PC
Lowell M. Zeta, Hogan Lovells US LLP